Adherium has announced that former Novartis executive Paul Mastoridis will succeed Rick Legleiter as CEO of the Hailie inhaler monitoring system maker. Legleiter recently announced his resignation from the company. Mastoridis was most recently Global Medical Head of Respiratory at Novartis and previously served as a brand director for respiratory at that company. Prior to Novartis, he held executive positions in Medical Affairs at Schering Plough, Angiotech, and Mylan.
Mastoridis said, “This is a fantastic opportunity to revolutionize how we manage millions of asthma and COPD patients globally. Adherium is a business with a strong brand portfolio and is a respected leader in patient adherence, remote monitoring and data management solutions for patients, physicians and payers. Our Hailie Smartinhaler technology and patient management system will lead the industry by bringing these innovative devices to patients to help them reduce their exacerbations, hospitalizations, deaths and live better lives.”
Adherium Independent Non-Executive Chair Lou Panaccio commented, “On behalf of my fellow directors, and the entire Adherium team, together with our valued shareholders and supporters, I welcome Dr. Mastoridis to the position of CEO. In particular, we are celebrating his investment of highly specialized intellectual capital and valuable global networks to our growing business.
Pacaccio added, “I would also like to formally thank our outgoing CEO, Rick Legleiter, who has served our company with focus, professionalism and integrity for the past 3 years – and who has committed to consulting to the board and management team for up to 6 months to ensure a smooth transition on all operational fronts to his successor.”
Read the Adherium press release.
